Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alvotech ( (ALVO) ) has provided an announcement.
On January 6, 2026, Alvotech disclosed insider-related share purchases reported to Luxembourg’s financial regulator, indicating increased ownership by entities closely associated with the company’s leadership. Alvogen Lux Holdings S.a.r.l., linked to Alvotech’s CEO and board members, acquired 7,007,321 Alvotech shares at SEK 44.06 per share in a transaction dated December 17, 2025, while ATP Holdings ehf. bought 4,812,257 shares on December 17, 2025, and an additional 2,110,640 shares on December 19, 2025, at the same price, signaling a significant vote of confidence from key stakeholders and potentially strengthening the company’s shareholder structure.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech, based in Luxembourg, is a foreign private issuer listed in the United States and operates in the biopharmaceutical sector, focusing on the development and commercialization of biosimilar medicines for global markets.
Average Trading Volume: 617,144
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.